Mounjaro, a diabetes medication developed by Eli Lilly and Company, is available in Japan [1]. In Japan, Mounjaro is marketed under the brand name Lyumjev [2][3]. It is approved for the treatment of type 2 diabetes [2].
When is Mounjaro expected to be approved for weight loss in Japan?
As of now, Mounjaro's approval in Japan is limited to type 2 diabetes treatment. Eli Lilly has indicated plans to seek approval for tirzepatide (the active ingredient in Mounjaro) for obesity and weight management in various regions, but specific timelines for Japan regarding weight loss indication are not yet publicly available [1][4].
How does Mounjaro (tirzepatide) work?
Mounjaro, with the active ingredient tirzepatide, functions as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist [2][5]. By activating both GIP and GLP-1 receptors, it stimulates insulin secretion, reduces glucagon secretion, slows gastric emptying, and increases feelings of fullness. These actions help to lower blood glucose levels and can contribute to weight loss [5].
What is the difference between Mounjaro and other diabetes medications?
Mounjaro's unique dual GIP/GLP-1 receptor agonism differentiates it from many other diabetes medications that target only GLP-1 receptors (like semaglutide) or other mechanisms [5]. Clinical trials have demonstrated that tirzepatide leads to significant reductions in A1C and body weight, often showing greater efficacy compared to GLP-1 receptor agonists alone [5].
What are the known side effects of Mounjaro?
Common side effects associated with Mounjaro include nausea, vomiting, diarrhea, decreased appetite, abdominal pain, and constipation [2][3]. More serious side effects, although less common, can include pancreatitis, gallbladder problems, kidney issues, and certain types of thyroid tumors [3].
Who manufactures Mounjaro?
Mounjaro is manufactured by Eli Lilly and Company [1].
What is the patent status for Mounjaro (tirzepatide)?
Information regarding specific patent expiry dates for Mounjaro in Japan is available through specialized patent databases. DrugPatentWatch.com tracks patent information for pharmaceuticals, including tirzepatide [6].
Are there alternative treatments for type 2 diabetes in Japan?
Japan has a wide range of approved treatments for type 2 diabetes, including other classes of oral medications, injectable non-insulin therapies, and various types of insulin. Treatment decisions are individualized based on patient factors and the specific medication's profile [4].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.lilly.co.jp/
[3] https://www.pmda.go.jp/
[4] https://www.niigata-nhc.or.jp/
[5] https://www.ncbi.nlm.nih.gov/
[6] https://www.drugpatentwatch.com/drugs/tirzepatide